A Narrative Review on Clinical Evidence of Tirzepatide’s Role in Addressing Type 2 Diabetes and Obesity Management
Abstract
Objective: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R) co-agonist, was initially approved for type 2 diabetes (T2D), and it later received US Food and Drug Administration (FDA) approval for managing overweight and obesity. This article aims to review the supporting clinical evidence of tirzepatide’s role in the treatment of T2D and obesity, shedding light on its potential impact on improving the health outcomes of individuals grappling with these conditions. Materials and methods: We obtained the clinical evidence from phase 1, 2, and 3 trials comprising the clinical development program for tirzepatide, SURPASS, and SURMONT for our review from the sources such as Google Scholar and PubMed. For studies reporting efficacy measures (e.g., changes in HbA1c levels, weight reduction), descriptive statistics were interpreted. For safety data, incidence rates of adverse events were reported. Results: Clinical trials across phases 1, 2, and 3 demonstrated that tirzepatide significantly reduced HbA1c levels and induced weight loss in diverse patient populations. The most commonly reported adverse events were gastrointestinal symptoms, including diarrhea (15–20%), nausea (20–30%), vomiting (10–15%), and abdominal pain, which were generally mild to moderate. Less frequent side effects included headache, fatigue, and occasional injection site reactions. Severe adverse events such as pancreatitis (> 1%) and acute kidney injury were rare but required careful monitoring during treatment. Conclusions: Tirzepatide has shown a favorable safety profile and effective management of T2D and obesity in clinical trials. Current research is assessing its effects on cardiovascular outcomes and chronic kidney disease, which could broaden its therapeutic applications.
Keywords: tirzepatidediabetesobesitySURPASSSURMOUNT
References
- Hameed I, Masoodi SR, Mir SA, et al. Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition. World J Diabetes. 2015; 6(4): 598–612.
- Naseralallah L, Aboujabal B. Profile of tirzepatide in the management of type 2 diabetes mellitus: design, development, and place in therapy. Expert Opin Pharmacother. 2023; 24(4): 407–418.
- Chavda VP, Ajabiya J, Teli D, et al. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022; 27(13).
- Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183: 109119.
- Chakhtoura M, Haber R, Ghezzawi M, et al. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. EClinicalMedicine. 2023; 58: 101882.
- Gallwitz B. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Front Endocrinol (Lausanne). 2022; 13: 1004044.
- Bailey CJ. Tirzepatide: a new low for bodyweight and blood glucose. Lancet Diabetes Endocrinol. 2021; 9(10): 646–648.
- Samms RJ, Christe ME, Collins KAl, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest. 2021; 131(12).
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018; 18: 3–14.
- Furihata K, Mimura H, Urva S, et al. A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. Diabetes, Obesity and Metabolism. Diabetes Obes Metab. 2022; 24(2): 239–246.
- Feng P, Sheng X, Ji Y, et al. A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes. Adv Ther. 2023; 40(8): 3434–3445.
- Frias JP. Prioritising injectable therapies in the management of type 2 diabetes. Lancet Diabetes Endocrinol. 2019; 7(7): 505–508.
- Frias J, Auchus R, Bancos I, et al. Abstract #1496147: CATALYST: A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies Assessing Prevalence and Treatment with Mifepristone. Endocrine Practice. 2023; 29(5): S122.
- Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021; 398(10300): 583–598.
- Del Prato S, Kahn SE, Pavo I, et al. SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021; 398(10313): 1811–1824.
- Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021; 398(10295): 143–155.
- Dahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022; 327(6): 534–545.
- Flaherty III SE, Bezy O, Paulhus BL, et al. SPAG7 deletion causes intrauterine growth restriction, resulting in adulthood obesity and metabolic dysfunction. Elife. 2024; 12(RP91114).
- Garvey WT, Frias JP, Jastreboff AM, et al. SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023; 402(10402): 613–626.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022; 387(3): 205–216.
- Jin T. Tirzepatide, a new class of incretin-based drug for diabetes. Obesity Medicine. 2023; 39: 100483.
- Moll H, Frey E, Gerber P, et al. GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study. EClinicalMedicine. 2024; 73: 102661.
- Garg SK, Akturk HK, Kaur G, et al. Efficacy and Safety of Tirzepatide in Overweight and Obese Adult Patients with Type 1 Diabetes. Diabetes Technol Ther. 2024; 26(6): 367–374.
- Kadowaki T, Chin R, Ozeki A, et al. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. Lancet Diabetes Endocrinol. 2022; 10(9): 634–644.
- Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021; 46: 101102.
- Bosch C, Carriazo S, Soler MJ, et al. Tirzepatide and prevention of chronic kidney disease. Clin Kidney J. 2023; 16(5): 797–808.
- Sinha R, Papamargaritis D, Sargeant JA, et al. Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management. J Obes Metab Syndr. 2023; 32(1): 25–45.